Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | MPO | P05164 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | BLM | P54132 | 1/20 | 0.70 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.70 |
| ▸ | TACR1 | P25103 | 2/20 | 0.60 |
| ▸ | HTR2A | P28223 | 2/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | HTR1D | P28221 | 1/20 | 0.60 |
| ▸ | HTR1B | P28222 | 1/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
| ▸ | HTR1E | P28566 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29850214 | 1.00 | KDM4E (0.70) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL631048 | 1.00 | KDM4E (0.70) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL4120269 | 1.00 | KDM4E (0.70) | KDM4EMAPTMEN1LMNAMPO | |
| Hydrochloric Acid SCHEMBL27780592 | 0.99 | KDM4E (0.68) | KDM4EMAPTMEN1LMNAMPO | |
| Hydrochloric Acid SCHEMBL8398299 | 0.99 | KDM4E (0.68) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL1069904 | 0.87 | KDM4E (0.72) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL27640891 | 0.87 | KDM4E (0.72) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL2250396 | 0.87 | MAPT (0.72) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL2250392 | 0.87 | MAPT (0.72) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL9609465 | 0.86 | MEN1 (0.71) | KDM4EMAPTMEN1LMNAMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004644-A1 | PROCESS FOR THE PREPARATION OF TADALAFIL | Glenmark Pharmaceuticals Limited (IN) | 2008-12-24 | — | — | EP | claimed |
| WO-2007110734-A1 | PROCESS FOR THE PREPARATION OF TADALAFIL | GLENMARK PHARMACEUTICALS LIMITED (US) | 2007-10-04 | — | — | WO | claimed |
| US-10624967-B2 | Targeted conjugates and particles and formulations thereof | TARVEDA THERAPEUTICS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-10322191-B2 | Targeted conjugates and particles and formulations thereof | TARVEDA THERAPEUTICS, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-20190125888-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2019-05-02 | — | — | US | disclosed |
| US-20190023690-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (CN) | 2019-01-24 | — | — | US | disclosed |
| US-9944628-B2 | Inhibitors of cellular necrosis and related methods | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944628-B2 | Inhibitors of cellular necrosis and related methods | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170312245-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2017-11-02 | — | — | US | disclosed |
| US-9499521-B2 | Inhibitors of cellular necrosis and related methods | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-11-22 | — | — | US | disclosed |
| US-20160304498-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-20 | — | — | US | disclosed |
| US-20120149702-A1 | INHIBITORS OF CELLULAR NECROSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8143300-B2 | Inhibitors of cellular necrosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110144169-A1 | Inhibitors of cellular necrosis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-06-16 | — | — | US | disclosed |
| WO-2010049500-A2 | A PROCESS FOR THE PREPARATION OF TADALAFIL. | CHEMO IBÉRICA, S.A. (ES) | 2010-05-06 | — | — | WO | disclosed |
| EP-2181997-A1 | A process for the preparation of tadalafil | Chemo Ibérica, S.A. (ES) | 2010-05-05 | — | — | EP | disclosed |
| EP-2004644-A1 | PROCESS FOR THE PREPARATION OF TADALAFIL | Glenmark Pharmaceuticals Limited (IN) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007110734-A1 | PROCESS FOR THE PREPARATION OF TADALAFIL | GLENMARK PHARMACEUTICALS LIMITED (US) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007110734-A1 | PROCESS FOR THE PREPARATION OF TADALAFIL | GLENMARK PHARMACEUTICALS LIMITED (US) | 2007-10-04 | — | — | WO | disclosed |
| US-6475985-B1 | Nucleosides with antiviral and anticancer activity | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2002-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190125888-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | SSTR4, SSTR5, SSTR1 | KDM4E 4457/4885MAPT 2389/4885MEN1 250/4885 |
| US-20160304498-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | LITAF, TNF, MMP8 | KDM4E 4639/4885MAPT 94/4885MEN1 2256/4885 |
| US-20110144169-A1 | Inhibitors of cellular necrosis | TNF, AIFM1, BAD | KDM4E 4662/4885MAPT 831/4885MEN1 4033/4885 |
| US-10624967-B2 | Targeted conjugates and particles and formulations thereof | SSTR5, SSTR1, SSTR4 | KDM4E 4717/4885MAPT 2143/4885MEN1 37/4885 |
| US-20120149702-A1 | INHIBITORS OF CELLULAR NECROSIS | TNF, AIFM1, BAD | KDM4E 4662/4885MAPT 831/4885MEN1 4033/4885 |
| US-10322191-B2 | Targeted conjugates and particles and formulations thereof | SSTR5, SSTR1, SSTR4 | KDM4E 4717/4885MAPT 2143/4885MEN1 37/4885 |
| US-20190023690-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | LITAF, TNF, MMP8 | KDM4E 4639/4885MAPT 94/4885MEN1 2256/4885 |
| US-20170312245-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | SSTR5, SSTR1, SSTR4 | KDM4E 4717/4885MAPT 2143/4885MEN1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.